Your browser doesn't support javascript.
SARS-CoV-2 infection risk among vaccinated and unvaccinated household members during the Alpha variant surge - Denver, Colorado, and San Diego, California, January-April 2021.
McCormick, David W; Konkle, Stacey L; Magleby, Reed; Chakrabarti, Ayan K; Cherney, Blake; Lindell, Kristine; Namageyo-Funa, Apophia; Visser, Susanna; Soto, Raymond A; Donnelly, Marisa A P; Stringer, Ginger; Austin, Brett; Beatty, Mark E; Stous, Sarah; Albanese, Bernadette A; Chu, Victoria T; Chuey, Meagan; Dietrich, Elizabeth A; Drobeniuc, Jan; Folster, Jennifer M; Killerby, Marie E; Lehman, Jennifer A; McDonald, Eric C; Ruffin, Jasmine; Schwartz, Noah G; Sheldon, Sarah W; Sleweon, Sadia; Thornburg, Natalie J; Hughes, Laura J; Petway, Marla; Tong, Suxiang; Whaley, Melissa J; Kirking, Hannah L; Tate, Jacqueline E; Hsu, Christopher H; Matanock, Almea.
  • McCormick DW; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, GA, USA; Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, GA, USA. Electronic address: yup1@cdc.gov.
  • Konkle SL; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, GA, USA; Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Magleby R; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, GA, USA; Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Chakrabarti AK; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Cherney B; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Lindell K; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Namageyo-Funa A; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Visser S; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Soto RA; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, GA, USA; Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Donnelly MAP; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, GA, USA; Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Stringer G; Colorado Department of Public Health and the Environment, Denver, CO, USA.
  • Austin B; County of San Diego Health and Human Services Agency, San Diego, CA, USA.
  • Beatty ME; County of San Diego Health and Human Services Agency, San Diego, CA, USA.
  • Stous S; County of San Diego Health and Human Services Agency, San Diego, CA, USA.
  • Albanese BA; Tri-County Health Department, Greenwood Village, CO, USA.
  • Chu VT; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, GA, USA; Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Chuey M; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, GA, USA; Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, GA, USA; County of San Diego Health and Human Services Agency, San Diego, CA, USA.
  • Dietrich EA; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Drobeniuc J; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Folster JM; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Killerby ME; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Lehman JA; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • McDonald EC; County of San Diego Health and Human Services Agency, San Diego, CA, USA.
  • Ruffin J; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Schwartz NG; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, GA, USA; Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Sheldon SW; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Sleweon S; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Thornburg NJ; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Hughes LJ; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Petway M; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Tong S; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Whaley MJ; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Kirking HL; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Tate JE; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Hsu CH; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Matanock A; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Vaccine ; 40(33): 4845-4855, 2022 08 05.
Article in English | MEDLINE | ID: covidwho-1915068
ABSTRACT

BACKGROUND:

COVID-19 vaccination reduces SARS-CoV-2 infection and transmission. However, evidence is emerging on the degree of protection across variants and in high-transmission settings. To better understand the protection afforded by vaccination specifically in a high-transmission setting, we examined household transmission of SARS-CoV-2 during a period of high community incidence with predominant SARS-CoV-2 B.1.1.7 (Alpha) variant, among vaccinated and unvaccinated contacts.

METHODS:

We conducted a household transmission investigation in San Diego County, California, and Denver, Colorado, during January-April 2021. Households were enrolled if they had at least one person with documented SARS-CoV-2 infection. We collected nasopharyngeal swabs, blood, demographic information, and vaccination history from all consenting household members. We compared infection risks (IRs), RT-PCR cycle threshold values, SARS-CoV-2 culture results, and antibody statuses among vaccinated and unvaccinated household contacts.

RESULTS:

We enrolled 493 individuals from 138 households. The SARS-CoV-2 variant was identified from 121/138 households (88%). The most common variants were Alpha (75/121, 62%) and Epsilon (19/121, 16%). There were no households with discordant lineages among household members. One fully vaccinated secondary case was symptomatic (13%); the other 5 were asymptomatic (87%). Among unvaccinated secondary cases, 105/108 (97%) were symptomatic. Among 127 households with a single primary case, the IR for household contacts was 45% (146/322; 95% Confidence Interval [CI] 40-51%). The observed IR was higher in unvaccinated (130/257, 49%, 95% CI 45-57%) than fully vaccinated contacts (6/26, 23%, 95% CI 11-42%). A lower proportion of households with a fully vaccinated primary case had secondary cases (1/5, 20%) than households with an unvaccinated primary case (66/108, 62%).

CONCLUSIONS:

Although SARS-CoV-2 infections in vaccinated household contacts were reported in this high transmission setting, full vaccination protected against SARS-CoV-2 infection. These findings further support the protective effect of COVID-19 vaccination and highlight the need for ongoing vaccination among eligible persons.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Observational study / Prognostic study Topics: Vaccines / Variants Limits: Humans Country/Region as subject: North America Language: English Journal: Vaccine Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Observational study / Prognostic study Topics: Vaccines / Variants Limits: Humans Country/Region as subject: North America Language: English Journal: Vaccine Year: 2022 Document Type: Article